Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy

Leukemia, Myeloid, Philadelphia-Positive Clinical Trial

Status Recruiting

Clinical Trial Summary

The study is controlled and randomized in Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients with complete cytogenetic response after more than one year of imatinib therapy. The aim is to explore a possible benefit in the addition of peg-interferon (Peg-IFN) to imatinib, in terms of the rate of achievement, molecular remission, and response duration.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid
• Leukemia, Myeloid, Philadelphia-Positive

• NCT number: NCT00297570
• Study type: Interventional
• Source: Sheba Medical Center
• Contact: Izhar Hardan, MD
• Phone: +972 3 5302174
• Email: izhar.hardan@sheba.health.gov.il
• Status: Recruiting
• Phase: Phase 3
• Start date: February 2006